Real-world treatment patterns and outcomes for patients with extensive-stage small-cell lung cancer treated in US community oncology practices - Takeaways - MDSpire

Real-world treatment patterns and outcomes for patients with extensive-stage small-cell lung cancer treated in US community oncology practices

  • By

  • Himani Aggarwal

  • Ke Zu

  • Carole R. Berini

  • Paul Conkling

  • Carlos Yugar

  • Jinhong Guo

  • Jerome Goldschmidt

  • May 22, 2026

  • 0 min

Share

  • 1

    Extensive-stage small-cell lung cancer (ES-SCLC) has a poor prognosis, with a 5-year survival rate of approximately 6.4%.

  • 2

    The most common first-line treatment for ES-SCLC is immune checkpoint inhibitors combined with platinum-based chemotherapy, used in 73.4% of patients.

  • 3

    Over half of the patients (58.0%) did not receive second-line therapy after initial treatment for ES-SCLC.

  • 4

    Median overall survival for patients receiving first-line treatment was 9.99 months, which decreased significantly in subsequent lines of therapy.

  • 5

    Despite the uptake of newer therapies, poor survival outcomes persist in ES-SCLC, indicating a need for novel treatment strategies.

Original Source(s)

Real-world treatment patterns and outcomes for patients with extensive-stage small-cell lung cancer treated in US community oncology practices

  • by Himani Aggarwal, Ke Zu, Carole R. Berini, Paul Conkling, Carlos Yugar, Jinhong Guo, Jerome Goldschmidt

  • May 22, 2026

Related Content

Trametinib as second-line therapy for advanced KRAS G12C-mutant non-small cell lung cancer: a single-center clinical analysis of 20 cases

Glioblastoma, IDH-wildtype, with a novel MEF2D-NTRK1 gene fusion: a case report

PD-1 inhibitor combined with chemoradiotherapy in two cases of ovarian cancer brain metastases: a case report